About ReviveMed
ReviveMed is a Healthcare company based in Cambridge (United States) founded in 2017. It operates as an AI-based metabolomics platform is developed for molecular data analysis. ReviveMed has raised $1.5 million across 2 funding rounds from investors including TechU Ventures, Rivas Capital and Team Builder Ventures. Its chief executive is Leila Pirhaji. ReviveMed offers products and services including AI Platform, Digital Metabolic Twins, and Generative Models. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is ReviveMed Inc. Its competitors include Personalis, Geneoscopy, OncoDNA, Ultivue and Strata Oncology and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
ReviveMed was founded in 2017 in Cambridge, United States, as a developer of an AI-based proprietary metabolomics platform. Integrative analysis is enabled through a network-based machine learning algorithm. Large-scale molecular information, including data from genes, proteins, drugs, and diseases, is provided. Operations focus on biotechnology applications for research and discovery in the life sciences sector.
- Headquarters Cambridge, United States
- SectorsHealthcare
- Email••••••••
- Website revivemed.io
- Social LinkedIn X Facebook
- Legal Name Revivemed Inc.
- Total Equity Funding$1.5M (USD)
in 2 rounds
- Latest Funding Round$1.5M (USD), Seed
Feb 2018
- InvestorsTechU Ventures
& 4 more
Products & Services of ReviveMed
ReviveMed offers a comprehensive portfolio of products and services, including AI Platform, Digital Metabolic Twins, and Generative Models.
AI system for metabolomics analysis and disease prediction in healthcare.
Virtual models simulating patient health and treatment responses using AI.
AI models for large-scale metabolomics data processing and annotation.
Funding Insights of ReviveMed
ReviveMed has successfully raised a total of $1.5M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.5 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.5M
- Total Rounds 2
- Last Round Seed — $1.5M
- Investors Count 5
All 2 funding rounds of ReviveMed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2018 | $1.5M | Seed | – | Rivas Capital | |
| May 2017 | – | Grant | – | – |
5 investors in total: 5 institutional.
Investors in ReviveMed
ReviveMed has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include TechU Ventures, Rivas Capital and Team Builder Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
TechU Ventures is involved in unspecified technology ventures. | – | techuventures.com | - | |
Investments in technology-based startups are made by Rivas Capital. | – | rivascap.com | Cambridge, United States | |
Venture capital fund investing in multiple sectors | – | teambuilderventures.com | San Francisco, United States | |
Venture capital fund and fund of funds focused on the United States-based startups and funds | – | worldquantventures.com | Greenwich, United States | |
Early-stage entrepreneurs are accelerated through MassChallenge's program. | – | masschallenge.org | Boston, United States |
Investor details for ReviveMed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReviveMed
1 people are tracked at ReviveMed (1 in leadership).
| Name | Role | Group |
|---|---|---|
Leila Pirhaji | CEO | Leadership |
Complete people profiles for ReviveMed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ReviveMed
3 dated milestones of ReviveMed across 1 years, from founding to its latest funding, stage changes and deals.
- Founded ReviveMed is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $1.5M.
Competitors of ReviveMed
ReviveMed has 10 listed competitors in our database, 9 of them funded. They include Personalis, Geneoscopy, OncoDNA, Ultivue and Strata Oncology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| geneoscopy.com | 2015 | St. Louis, United States | $218.95M | – | Non-invasive biomarker tests for colorectal cancer are developed. | |
| oncodna.com | 2012 | Charleroi, Belgium | $44.53M | 37 | Genomic and theranostic services for oncology precision medicine are delivered. | |
| ultivue.com | 2015 | Cambridge, United States | $105.23M | – | Provider of test panels for personalized cancer therapies | |
| strataoncology.com | 2015 | Ann Arbor, United States | $139.15M | 125 | Genetic sequencing is provided for late-stage cancer patients. | |
| rootpath.com | 2017 | Cambridge, United States | $68M | 16 | Immunotherapy platform is developed for personalized cancer treatment. | |
| precede.bio | 2021 | Boston, United States | $57M | – | Circulating chromatin is profiled via liquid-biopsy platform for cancer diagnosis. | |
| saladax.com | 2004 | Bethlehem, United States | $46.32M | 17 | Diagnostic tests for personalized oncology chemotherapy are provided. | |
| opko.com | 1991 | Miami, United States | – | 3,930 | Molecular diagnostic products for prostate cancer assessment are provided. | |
| adelabio.com | 2021 | San Francisco, United States | $133.97M | – | Cancer detection platform via blood-based methylation analysis is developed. |
Detailed competitors of ReviveMed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ReviveMed
The website of ReviveMed (revivemed.io) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 456% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as ReviveMed (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Revivemed
Complete news archive for ReviveMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReviveMed
ReviveMed was founded in 2017.
ReviveMed is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Leila Pirhaji is the current CEO of ReviveMed.
ReviveMed is a funded company, having raised a total of $1.5M across 2 funding rounds to date.
ReviveMed was founded in 2017 in Cambridge, United States, as a developer of an AI-based proprietary metabolomics platform. Integrative analysis is enabled through a network-based machine learning algorithm. Large-scale molecular information, including data from genes, proteins, drugs, and diseases, is provided. Operations focus on biotechnology applications for research and discovery in the life sciences sector.
ReviveMed's top competitors include Personalis, Geneoscopy and OncoDNA.
ReviveMed offers AI Platform, Digital Metabolic Twins, and Generative Models.
ReviveMed has 5 investors. Key investors include TechU Ventures, Rivas Capital, Team Builder Ventures, WorldQuant Ventures, and MassChallenge.
ReviveMed operates through Revivemed Inc..